Wednesday, 20 Mar 2019

RA/Inflammatory arthritis

Datesort ascending Type Title Save
26 Sep 2018 Social Analysis of eteran's Affairs RA data from 2006 to 2012, looked at escalating from MTX to MTX‐TNFi or triple therapy shows nonpersistence with triple Rx is related to AE from SSZ use. https://t.co/MBGMrnwKj0
25 Sep 2018 Social Patients with preclinical RA (1st degree relative, serology+, arthralgia) should definitely change lifestyle before talking to their Rheumatologist about potential benefit/hazards of DMARD therapy. https://t.co/h4gpJgHHCw
25 Sep 2018 Social RT @sclerodermaUM: We received great feedback on our Self-Manage #Scleroderma newsletter. "Your email is ABSOLUTELY WONDERFUL! I hope this…
22 Sep 2018 Social Open study of adalimumab and infliximab in recalcitrant (RV) retinal vasculitis (unresponsive to other therapies) - 48 pts Rx (1/2 ADA, 1/2 INFL) - RV remission within 54% @3 mos and 86% @ 12 mos. with no added benefit to other cotherapies. https://t.co/EvbFj6vXly
20 Sep 2018 Social Chronic back pain suspected of having axial spondyloarthritis (axSpA) should not undergo follow-up MRI of the sacroiliac joint (MRI-SI) within a year if they had a previously negative baseline MRI-SI https://t.co/OoXDzcBTNd
20 Sep 2018 News Treat-to-Target in RA: No Increase in AEs
16 Sep 2018 Social FDA approves SC Actemra (tocilizumab) for systemic JIA (Stills disease) +/-MTX. IV TCZ was FDA approved In 2011 for SJIA. Approval is based on JIGSAW, a 52-wk study. sJIA dosing based on Weight ( <30 kg-162 mg q2wk; ≥30 162 mg qwk) https://t.co/kWXdwAh35Z
14 Sep 2018 Social Systemic onset JIA patients may have higher Injection Site Reaction rates when taking sc tocilizumab (45% sJIA) compared to polyarticular JIA (15-29%). RA ( 7-10%) or GCA https://t.co/ooDo1LjGlA
12 Sep 2018 Social RT @DrAiLynTan: In a difficult-to-treat #rheumatoid #arthritis survey ➡️50% chose DAS28>3.2 or presence of signs suggestive of active dise…
12 Sep 2018 News Mediterranean Diet Reduces Risk of Rheumatoid Arthritis
11 Sep 2018 Social 12 mos study (U-Act-Early) 108 Rx naive RA patients were treated in a T2T manner w/ MTX and then HCQ and tofacitinib added after 6 mos w/ inadequate response. @12 mos IR was seen in 52% and predicted by Higher DAS28, current smoking and no alcohol intake https://t.co/mkaNQ8AyME
10 Sep 2018 Social Gilead and Galapagos Announce TORTUGA Phase 2 Study of Filgotinib (JAK 1 inhib) in Ankylosing Spondylitis with filgotinib ASAS20 response of 76% vs 40% PBO response (p<0.0001). https://t.co/0s8xc8za4h
10 Sep 2018 Social #Scleroderma Research Foundation will collaborate with 11 US universities in establishing CONQUER: a national, longitudinal patient registry for scleroderma. Leaders include Victoria Shanmugan (GWU), Jessica Gordon (HSS), & Shervin Assassi (UT Houston) https://t.co/lKs4W14iNI
10 Sep 2018 Social Red cell distribution width RDW interpretation is a useful tool in clinical practice to distinguish between articular inflammatory and non‐inflammatory joint diseases, as with CRP. RDW seems to be a surrogate marker of the inflammatory process. https://t.co/Z2Ql5FZMxH
10 Sep 2018 Social 325 pts with Early RA received either MTX or MTX + HCQ. At 6 mos the combination MTX/HCQ patients had signifificantly greater EULAR good responses and DAS28-CRP values; but differences were less by 12 mos. Rx intensification was more in MTX monoRx group https://t.co/zTy0KNx1X7
05 Sep 2018 Social RT @DrPetryna: Rheum disease associated secondary MAS does not only happen in auto-inflammatory syndromes; it can complicate virtually any…
31 Aug 2018 Social Unmet Needs in in Still’s Disease -results of 257 Rheum Survey on how to treat, when to use biologic, best biologic & more. Did you know that 20% of Rheums dont see Stills and 60% of referrals from PCP, Hospitalists & ID Docs https://t.co/iv300uSO8J’s-disease#.W4iPBanKroM.twitter
29 Aug 2018 Social My observation is that new consults who present for joint issues while on ADHD meds are likely to have sleep and myofascial pain problems (alone or in addition to other findings)
26 Aug 2018 Social Adult, Acute, Asymmetric Oligoarticular inflammatory arthritis - Whats your differential Dx? PsA, Spa, Reactive, IBD, Sarcoid, undifferentiated arthritis, CPPD, RA, chlamydia, Lyme ? Dont forget Gout, gonococccal Arthritis, TB!
24 Aug 2018 Social Treatments Do Not Increase Infection Risk in Ankylosing Spondylitis | RheumNow - Rheumatology News & Information https://t.co/YTvDyOAzSN